Cargando…
Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis
INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodie...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916700/ https://www.ncbi.nlm.nih.gov/pubmed/27297011 http://dx.doi.org/10.1136/bmjopen-2016-011113 |
_version_ | 1782438866422071296 |
---|---|
author | Eusebi, Paolo Giannandrea, David Biscetti, Leonardo Abraha, Iosief Chiasserini, Davide Orso, Massimiliano Calabresi, Paolo Parnetti, Lucilla |
author_facet | Eusebi, Paolo Giannandrea, David Biscetti, Leonardo Abraha, Iosief Chiasserini, Davide Orso, Massimiliano Calabresi, Paolo Parnetti, Lucilla |
author_sort | Eusebi, Paolo |
collection | PubMed |
description | INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodies (LBs), which are intracytoplasmic inclusions in substantia nigra neurons. The major component of LBs, α-synuclein (α-syn), has been implicated in the pathogenesis of PD and in other ‘synucleinopathies’ such as multisystem atrophy (MSA) and dementia with LBs (DLBs). Several studies have investigated this presynaptic protein as a potential biomarker of PD. The aim of our meta-analysis is to determine the ability of cerebrospinal fluid (CSF) concentrations of total α-syn, oligomeric α-syn and phosphorylated α-syn to discriminate patients with PD from healthy participants, non-degenerative neurological controls and patients suffering from parkinsonism and or synucleinopathies. METHODS AND ANALYSIS: This systematic review protocol has been developed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocol (PRISMA-P) 2015 statement and was registered on PROSPERO (CRD42016013217). We will search Cochrane Library, Web of Science, MEDLINE (via PubMed) and EMBASE from inception, using appropriate search strategies. Two independent reviewers will screen titles, abstracts and full-text articles, and will complete data abstraction. We will include studies that involved patients with PD, DLB, MSA, progressive supranuclear palsy, corticobasal disease and vascular PD, and in which at least one between total α-syn, oligomeric α-syn and phosphorylated α-syn was measured in CSF. To evaluate the risk of bias and applicability of primary diagnostic accuracy studies, we will use QUADAS-2. ETHICS AND DISSEMINATION: Our study will not include confidential data, and no intervention will be involved, so ethical approval is not required. The results of the study will be reported in international peer-reviewed journals. |
format | Online Article Text |
id | pubmed-4916700 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49167002016-06-24 Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis Eusebi, Paolo Giannandrea, David Biscetti, Leonardo Abraha, Iosief Chiasserini, Davide Orso, Massimiliano Calabresi, Paolo Parnetti, Lucilla BMJ Open Neurology INTRODUCTION: The diagnostic criteria currently used for Parkinson's disease (PD) are mainly based on clinical motor symptoms. For these reasons many biomarkers are under investigation to support the diagnosis at the early stage. The neuropathological hallmark of PD is represented by Lewy bodies (LBs), which are intracytoplasmic inclusions in substantia nigra neurons. The major component of LBs, α-synuclein (α-syn), has been implicated in the pathogenesis of PD and in other ‘synucleinopathies’ such as multisystem atrophy (MSA) and dementia with LBs (DLBs). Several studies have investigated this presynaptic protein as a potential biomarker of PD. The aim of our meta-analysis is to determine the ability of cerebrospinal fluid (CSF) concentrations of total α-syn, oligomeric α-syn and phosphorylated α-syn to discriminate patients with PD from healthy participants, non-degenerative neurological controls and patients suffering from parkinsonism and or synucleinopathies. METHODS AND ANALYSIS: This systematic review protocol has been developed according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses Protocol (PRISMA-P) 2015 statement and was registered on PROSPERO (CRD42016013217). We will search Cochrane Library, Web of Science, MEDLINE (via PubMed) and EMBASE from inception, using appropriate search strategies. Two independent reviewers will screen titles, abstracts and full-text articles, and will complete data abstraction. We will include studies that involved patients with PD, DLB, MSA, progressive supranuclear palsy, corticobasal disease and vascular PD, and in which at least one between total α-syn, oligomeric α-syn and phosphorylated α-syn was measured in CSF. To evaluate the risk of bias and applicability of primary diagnostic accuracy studies, we will use QUADAS-2. ETHICS AND DISSEMINATION: Our study will not include confidential data, and no intervention will be involved, so ethical approval is not required. The results of the study will be reported in international peer-reviewed journals. BMJ Publishing Group 2016-06-13 /pmc/articles/PMC4916700/ /pubmed/27297011 http://dx.doi.org/10.1136/bmjopen-2016-011113 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Neurology Eusebi, Paolo Giannandrea, David Biscetti, Leonardo Abraha, Iosief Chiasserini, Davide Orso, Massimiliano Calabresi, Paolo Parnetti, Lucilla Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title_full | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title_fullStr | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title_full_unstemmed | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title_short | Diagnostic utility of CSF α-synuclein species in Parkinson's disease: protocol for a systematic review and meta-analysis |
title_sort | diagnostic utility of csf α-synuclein species in parkinson's disease: protocol for a systematic review and meta-analysis |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916700/ https://www.ncbi.nlm.nih.gov/pubmed/27297011 http://dx.doi.org/10.1136/bmjopen-2016-011113 |
work_keys_str_mv | AT eusebipaolo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT giannandreadavid diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT biscettileonardo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT abrahaiosief diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT chiasserinidavide diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT orsomassimiliano diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT calabresipaolo diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis AT parnettilucilla diagnosticutilityofcsfasynucleinspeciesinparkinsonsdiseaseprotocolforasystematicreviewandmetaanalysis |